Aneurysmal Subarachnoid Hemorrhage Market - Forecast(2024 - 2030)

Aneurysmal Subarachnoid Hemorrhage Market Overview

The Aneurysmal Subarachnoid Hemorrhage Market size is estimated to reach $282.4 million by 2027. Furthermore, it is poised to grow at a CAGR of 3.9% over the forecast period of 2022-2027. aSAH or Aneurysmal Subarachnoid Hemorrhage is a form of bleeding in the space which surrounds the brain. Further, it occurs when a weak area within a blood vessel on the surface of the brain bursts or leaks. The following condition can lead to increased pressure on the brain and can lead to coma, brain cell damage, life-long complications, and worse death. The fatality from the said form of intracranial aneurysm nears 45% and has an incidence of nearly 5-7% of all intracerebral strokes. Further, delayed cerebral ischemia occurs days after one suffers a subarachnoid hemorrhage and represents a potentially treatable cause of morbidity, as approximately one-third of those who survive the first stint can live through the ischemia. Furthermore, clinical researchers have established that a sustained form of hypernatremia will benefit patients in short-term neurological outcomes. Moreover, the growing old population supplemented by various forms of co-morbid conditions supplemented by government fiscal supports would allow the Aneurysmal Subarachnoid Hemorrhage Industry to grow at an optimal pace during the projected period of 2022-2027.

Aneurysmal Subarachnoid Hemorrhage Market Report Coverage

The report: “Aneurysmal Subarachnoid Hemorrhage Market Forecast (2022-2027)”, by Industry ARC covers an in-depth analysis of the following segments of the Aneurysmal Subarachnoid Hemorrhage Market.

By Diagnostic Test Type- CT scan, MRI, Cerebral Angiography, Lumbar Puncture, and Transcranial Doppler Ultrasound.

By Treatment- Microsurgery Clipping, Endovascular Embolization, and Others.

By End Users- Hospitals, Clinics, ASCs, and Others.

By Geography- North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America), and Rest of the World (the Middle East, and Africa)

Key Takeaways

• Geographically, North America’s aneurysmal subarachnoid hemorrhage market held a dominant market share in the year 2021. The following form of stroke is often leaded by various co-morbid conditions such as hypertension, chronic alcoholism, kidney diseases, substance abuse, and various other conditions. All the said medical complications are extremely prevalent in the region, which allows the market to hold higher revenues.
• The rising expenditure and technological upgrades to advance medical imaging along with rising traumatic incidents and geriatric age are some of the leading factors driving the Aneurysmal Subarachnoid Hemorrhage Market. However, extremely lower chances of survival along with complex physiological requirements impede market growth.
• A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Aneurysmal Subarachnoid Hemorrhage Market Report.

  Aneurysmal Subarachnoid Hemorrhage Market- Geography (%) for 2021.

  
  

  For more details on this report - Request for Sample

Aneurysmal Subarachnoid Hemorrhage Market Segment Analysis- By Diagnostic Type

The aneurysmal subarachnoid hemorrhage market based on diagnostic type can be further segmented into CT scan, MRI, Cerebral Angiography, Lumbar Puncture, and Transcranial Doppler Ultrasound. MRI or Magnetic Resonance Imaging held a dominant market share in the year 2021. The following test uses large magnets, radiofrequency energy, and a computer to gauge a detailed image of the brain. Additionally, MRI has been gaining dense market penetration and is now often recommended by neurologists and ER doctors owing to its higher efficacy when compared to CT scans. As per a PUBMED trial, MRI was able to detect cases of hemorrhagic transformations, which CT was unable to do. For the diagnosis of any hemorrhage, MRI was positive in 71 patients with CT positive in 29. Additionally, in some of the trials, it was concluded that MRI is more credible for the detection of chronic intracerebral hemorrhage. However, Lumbar Puncture is estimated to be the fastest-growing, with a CAGR of 4.6% over the forecast period of 2022-2027. Within the said procedure, a needle is inserted in the lower back to withdraw a small amount of fluid that surrounds the brain and spinal cord. The examination opines a better clinical roadmap and is positively correlated with the indication of subarachnoid hemorrhage. Lastly, as per Mayo Clinic, up to 22% of aneurysmal subarachnoid hemorrhages won’t appear on initial imaging tests, hence doctors often need to perform another form of screening or blood tests to re-assure.

Aneurysmal Subarachnoid Hemorrhage Market Segment Analysis- By Treatment

The aneurysmal subarachnoid hemorrhage market based on treatment can be further segmented into Microsurgery Clipping, Endovascular Embolization, and Others. Microsurgery Clipping held a dominant market share in the year 2021. The technique focuses on cutting off the blood supply to a brain aneurysm, which would prevent it from rupturing or even help in controlling the bleeding if a rupture has already occurred. Post performing a craniotomy, the neurosurgeon places a small metal clip on the opening (aneurysm), which would obstruct the blood flow. Since the fatality rate of the following aneurysm touched the mark of 45%, it becomes essential to stop the bleeding at the earliest, to substantiate the living chances. However, endovascular embolization/ coiling is estimated to be the fastest-growing, with a CAGR of 4.9% over the forecast period of 2022-2027. The following form of the procedure makes a tiny incision in one’s groin, and a catheter is passed through the artery from the leg to the one part of the brain which is bleeding. Recovery time post such hemorrhage is shorter and is often recommended for the elderly population or with people with the comorbid condition.

Aneurysmal Subarachnoid Hemorrhage Market Segment Analysis- By Geography

The aneurysmal subarachnoid hemorrhage market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held a dominant market share of 35% in the year 2021. As per NCBI, the estimated prevalence of aSAH globally is 9/100,000. However, the said ratio breaches the general average for the likes of the U.S. with prevalence close to 10/100,000. It is owing to a prevalence of widespread comorbidity within the region. As per CDC, around 51.8% of adults within the region have at least one chronic condition, with around 27.2% suffering from multiple chronic conditions. Furthermore, medical research capabilities and government support via Medicare facilities and others allow people to gain medical facilities. Lastly, research has surfaced claiming a strong correlation between marijuana usage and higher chances of developing intracerebral hemorrhage. CDC estimates govern that around 18% of Americans have had at least tried marijuana in a year. However, Asia-Pacific is expected to offer lucrative growth opportunities over the forecast period of 2022-2027. It is owing to the growing geriatric population and better medicinal capabilities in countries such as China, India, Japan, and Korea. Interestingly, a systematic review revealed that around 22.7/100,000 has been the incidence for aSAH.

Aneurysmal Subarachnoid Hemorrhage Market Drivers

The growing geriatric population coupled with their tendency to suffer from falls and other forms of ailments have been a key market driver.

The geriatric population has been growing around the world. One of the predominant featurettes which lead to complications within the said form of hemorrhage is old age coupled with various forms of health complications such as hypertension, diabetes, or any other dependency on anti-coagulant treatments.  As per a large study cohort conducted by NCBI, it was deduced that elevated blood pressure following a SAH has been associated with higher mortality. Moreover, a sustained elevation of BP increases the risk for aneurysmal rupture and rebleeding. Hypertension has been a key part of the old as well as the young, as per WHO there are around 700 million cases of untreated hypertension throughout the world. Additionally, blood pressure worries along with diabetes have been a concerning facet for the old and frail population-which induces the chances to develop such form of hemorrhage, as they are more susceptible to falls. As per CDC guides, more than one out of every four elder falls within the States, and deaths owing to such injuries can accumulate and lead to up to 7 Fall Deaths per hour. As per CDC estimates, around 59 million people in the U.S. were above 65, and the said numbers are bound to grow and touch 95 million by 2060. Additionally, as per OECD estimates, fertility rates within the low-and-middle-income countries of Asia-Pacific have reduced to 2.1, while the older population is set to increase by nearly 2.5x in the same regions. Owing to these factors, the market is positioned favorably.

The rising facet of urbanization coupled with an increase in road accidents and substance abuse have allowed the market to grow.

Urbanization has been a leading reason for such form of hemorrhage, or at least they induce various habits and nuances which in turn increases the chances of developing conditions such as aneurysmal subarachnoid hemorrhage. As per John Hopkins Medicine, subarachnoid hemorrhage is caused by a hemorrhagic stroke or bleeding within the brain. Further, scientific literature has time and again proven that intracerebral hemorrhage can be a strong result of drug or substance abuse. Urbanization often leads people to extreme stress and monotony, which tends people to try various new drugs or substances. Cocaine and Fentanyl (a form of opioid) are some of the recognized forms of substance abuse which are growing within the countries such as the U.S. As per the Drug Enforcement Administration, around two milligrams of fentanyl are lethal-and one kilogram of fentanyl has the capability to kill around 500,000 people. Within the fiscal year of 2021, the fentanyl bust was close to 41 pounds which is a 4000% increase when last year's data is compared. Lastly, road accidents can lead to heightened chances of bleeding and hemorrhage. The numbers for which have been growing. As per World Bank, around 450,000 accidents take place in India annually- of which nearly 150,000 people die owing to late emergency care or heavy internal bleeding, or others. Owing to such trends, the market is positioned favorably.

Aneurysmal Subarachnoid Hemorrhage Market Challenges

The high fatality rates owing to the extremity of the condition along with the higher cost associated impedes the market growth.

The condition pertaining to aneurysmal subarachnoid hemorrhages is extremely fragile owing to the emergency nature coupled with complex physiology and varied intracranial and systemic manifestations. In a cohort study presented by NCBI, it was found that Hyperglycaemia was found to be associated with increased length of ICU stay, and increased risk of death and disability. The study further depicted that people who had the following condition and underwent the clipping procedural routine and had their blood sugar levels >129 mg/dl were more prone to long-term cognitive dysfunction. Moreover, diabetes has been extremely prevalent in today’s world. As per CDC, >10.1% of the U.S. population have or are on the verge to develop diabetes. Moreover, there is a growing number of aneurysm cases that are incidental in nature and are often diagnosed towards the very end-thereby inducing heavy medical cost.

Aneurysmal Subarachnoid Hemorrhage Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Aneurysmal Subarachnoid Hemorrhage Market. Aneurysmal Subarachnoid Hemorrhage Market Top-10 companies are:

1. Actelion Pharmaceutical Ltd,
2. Edge Therapeutics Inc,
3. Arbor Pharmaceuticals,
4. Mayfield Brain and Spine,
5. Europa Group,
6. GE Healthcare,
7. Trivitron Healthcare,
8. Siemens AG,
9. Toshiba Medical Systems Corporation,
10. Koninklijke Philips NV

Recent Developments

• In January 2022, Idorsia received Japanese PMDA approval for its PIVLAZ (Clazosentan Sodium) 150 mg. PIVLAZ is an ETA receptor antagonist which is used for the prevention of cerebral vasospasm, vasospasm-related cerebral infraction, and cerebral ischemic symptoms after one suffer from Aneurysmal Subarachnoid Hemorrhage or aSAH. The approval comes in light with the dedicated Japanese Phase 3 Program.
• In November 2021, Philips launched a series of new MRI scanners which have the potential to identify a wide range of diseases ranging from heart complications to brain anomalies. The products launched are a new range of 1.5 Tesla and 3-Tesla MRI scanners, moreover, software-based workflow enhancements which are designed to enable radiology thereby allowing for more efficient facilities. A number of enhancements are powered by artificial intelligence (AI) to improve workflow, efficiency, and image quality. The scanner is able to simplify and automate many complex clinical and operational tasks, according to the company.
• In April 2021, A clinical trial was conducted to identify circulating biomarkers, such as IL-6 within the cerebrospinal fluid small extracellular vesicles for prognosis of aSAH (Aneurysmal Subarachnoid Hemorrhage). The results went in favor as CSF IL-6 showed distinctive pattern differences between the study group and control groups. IL-6_sEVs levels were greater and positively associated with disease processes and outcomes. Lastly, the conclusion aided as a market opportunity to publicize the use of IL-6 as a critical biomarker.

Relevant Titles